Effect of poloxamer on physicochemical properties of tacrolimus solid dispersion improving water solubility and dissolution rate

Journal of Pharmaceutical Investigation

Volumn 42, Issue 4, 2012, Pages 171-176

  Ha, Jung Myung ^a   Kang, Seung Yeob ^a   Park, Chun Woong ^a   Bin, Sung A ^a   Rhee, Yun Seok ^b   Seo, Jeong Woong ^a   Kim, Su Heon ^a   Chi, Sang Cheol ^a   Park, Eun Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Gyeongsang National University   (South Korea)

Author keywords

Hot melting method; Poloxamer; Solid dispersion; Solubility improvement; Tacrolimus

Indexed keywords

ACETONE; ALCOHOL; CHLOROFORM; METHANOL; POLOXAMER; TACROLIMUS;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SOLID DISPERSION; SUSPENSION; THERMOGRAPHY; X RAY DIFFRACTION;

EID: 84870340772     PISSN: 20935552     EISSN: 20936214     Source Type: Journal    
DOI: 10.1007/s40005-012-0025-4     Document Type: Article

References (30)

1. Betageri G, Makarla K (1995) Enhancement of dissolution of glyburide by solid dispersion and lyophilization techniques. Int J Pharm 126: 155-160.
2. Borhade V, Nair H, Hegde D (2008) Design and evaluation of self-micro emulsifying drug delivery system (SMEDDS) of tacrolimus. AAPS Pharm Sci Tech 9: 13-21.
3. Dubois J-L, Ford JL (1985) Similarities in the release rates of different drugs from polyethylene glycol 6, 000 solid dispersions. J Pharm Pharmacol 37: 494-495.
4. Francés C, Veiga MD, Español OM, Cadórniga R (1991) Preparation, characterization and dissolution of ciprofloxacin/PEG 6000 binary systems. Int J Pharm 77: 193-198.
5. Haufroid V, Mourad M, van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, Malaise J, Lison D, Squifflet JP, Wallemacq P (2004) The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenet Genomics 14: 147.
6. Hirasawa N, Okamoto H, Danjo K (1999) Lactose as a low molecular weight carrier of solid dispersions for carbamazepine and ethenzamidc. Chem Pharm Bull Tokyo 47: 417-420.
7. Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y (1987) The oral dosage form of FK-506. Transpl Proc 19(5 Suppl 6): 17.
8. Janssens S, van den Mooter G (2009) Review: physical chemistry of solid dispersions. J Pharm Pharmacol 61: 1571-1586.
9. Joe JH, Lee WM, Park YJ, Joe KH, Oh DH, Seo YG, Woo JS, Yong CS, Choi HG (2010) Effect of the solid-dispersion method on the solubility and crystalline property of tacrolimus. Int J Pharm 395: 161-166.
10. Jung JY, Yoo SD, Lee SH, Kim KH, Yoon DS, Lee KH (1999) Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm 187: 209-218.
11. Kaur R, Grant D, Eaves T (1980) Comparison of polyethylene glycol and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin and tolbutamide II. J Pharm Sci 69: 1321-1326.
12. Kushida I, Ichikawa M, Asakawa N (2002) Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J Pharm Sci 91: 258-266.
13. Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y (2004) Design of pH-sensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. Eur J Pharm Biopharm 58: 37-43.
14. Law S, Lo W, Lin F, Chaing C (1992) Dissolution and absorption of nifedipine in polyethylene glycol solid dispersion containing phosphatidylcholine. Int J Pharm 84: 161-166.
15. Nassar T, Rom A, Nyska A, Benita S (2009) Novel double coated nano capsules for intestinal delivery and enhanced oral bioavailability of tacrolimus, a P-gp substrate drug. J Control Release 133: 77-84.
16. Park YJ, Ryu DS, Li DX, Quan QZ, Oh DH, Kim JO, Seo YG, Lee YI, Yong CS, Woo JS (2009) Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. Arch Pharm Res 32: 893-898.
17. Patel PS, Raval JP, Patel HV (2010) Review on the pharmaceutical applications of hot melt extruder polymer. J Pharm Clin Res 3: 80-83.
18. Perng CY, Kearney AS, Patel K, Palepu NR, Zuber G (1998) Investigation of formulation approaches to improve the dissolution of SB-210661, a poorly water soluble 5-lipoxygenase inhibitor. Int J Pharm 176: 31-38.
19. Saers ES, Craig DQM (1982) An investigation into the mechanisms of dissolution of alkyl p-aminobenzoates from polyethylene glycol solid dispersions. Int J Pharm 83: 211-219.
20. Sekiguchi K, Obi N (1961) Studies on absorption of eutectic mixture. I. A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull 9: 866-872.
21. Serajuddin A (1999) Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci 88: 1058-1066.
22. Sharma D, Soni M, Kumar S, Gupta G (2009) Solubility enhancement-eminent role in poorly soluble drugs. Res J Pharm Technol 2: 220-224.
23. Shin SB, Cho HY, Kim DD, Choi HG, Lee YB (2010) Preparation and evaluation of tacrolimus-loaded nanoparticles for lymphatic delivery. Eur J Pharm Biopharm 74: 164-171.
24. Simonelli AP, Mehta SC, Higuchi WI (1969) Dissolution rates of high energy polyvinylpyrrolidone (pvp)-sulfathiazole coprecipitates. J Pharm Sci 58: 538-549.
25. Tantishaiyakul V, Kaewnopparat N, Ingkatawornwong S (1999) Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int J Pharm 181: 143-151.
26. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, Legendre C, Daly AK (2003) Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients 12. Transplantation 76: 1233.
27. Wang Y, Wang C, Fu S, Liu Q, Dou D, Lv H, Fan M, Guo G, Luo F, Qian Z (2011) Preparation of tacrolimus loaded micelles based on poly (e{open}-caprolactone)-poly (ethylene glycol)-poly (e{open}-caprolactone). Int J Pharm 407: 184-189.
28. Wong SHY (2001) Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta 313: 241-253.
29. Yamashita K, Nakate T, Okimoto K, Ohike A, Tokunaga Y, Ibuki R, Higaki K, Kimura T (2003) Establishment of new preparation method for solid dispersion formulation of tacrolimus. Int J Pharm 267: 79-91.
30. Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74: 571.